# GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

> **NCT00158899** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 424 (actual)

## Conditions studied

- Dyslipidaemias
- Dyslipidaemia

## Interventions

- **DRUG:** GW501516 oral tablets

## Key facts

- **NCT ID:** NCT00158899
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 424 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00158899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00158899, "GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00158899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*